For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis
Objective : Identifying and effectively treating erectile dysfunction ( ED ) can result in an improvement of the quality of life ( QoL ) in men with multiple sclerosis ( MS ) . Methods : This r and omised , double blind ( DB ) , placebo controlled , flexible dose study with an open label extension ( OLE ) assessed efficacy , QoL , and safety of sildenafil citrate in men with MS and ED . Overall , 217 men received sildenafil ( 25–100 mg ; n = 104 ) or placebo ( n = 113 ) for 12 weeks . Efficacy was assessed by the International Index of Erectile Function ( IIEF ) question naire that includes questions on achieving ( Q3 ) and maintaining ( Q4 ) an erection as well as a global efficacy question ( GEQ ) . QoL was also assessed . Results : After 12 weeks , patients receiving sildenafil had higher mean scores for IIEF Q3 and Q4 compared with those receiving placebo ( p<0.0001 ) , and 89 % ( 92/103 ) reported improved erections compared with 24 % ( 27/112 ) of patients receiving placebo ( p<0.0001 ) . At the end of the OLE phase , 95 % of men reported improved erections . Patients receiving placebo during the DB phase showed a nearly fourfold increase in improved erections ( 97 % v 26 % ) . Men receiving sildenafil also showed improvements in five of the eight general QoL questions compared with men receiving placebo ( p<0.05 ) . The total mean score for the QoL question naire improved by 43 % for the sildenafil group versus 13 % for the placebo group ( p<0.0001 ) . Treatment related AEs were predominantly mild in nature , and no patient discontinued due to an AE . Conclusion : Sildenafil treatment for ED in men with MS was effective and well tolerated , and result ed in significant improvements in both general and disease specific QoL variables
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .